5 Investor presentation First nine months of 2023 Sales growth of 33% driven by bo Reported geographic sales split for first nine months of 2023 DKK billion Insulin Obesity care GLP-1 Rare disease Other diabetes Growth at CER 100 49% 80 17% International Operations 60 40 19% 16% 20 12% 0 NAO IO EMEA China RoW 1 ‘Other diabetes’ is included in Total IO: International Operations; EMEA: Europe, Middle East and Africa; China: Mainland China, Hong Kong and Taiwan; RoW: Rest of W Note: Unless otherwise specified, sales growth rates are at CER
Download PDF file